The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Could BTK inhibitors still play a role in treating follicular lymphoma?
To date, BTK inhibitors have demonstrated limited efficacy as monotherapy in follicular lymphoma (FL). In this interview, Jessica Allen, MD, Huntsman Cancer Institute, Salt Lake City, UT, briefly discusses whether these agents may still play a role in FL, specifically in combination with other drug classes, such as bispecific antibodies. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
